Correlation of HLA-DR antigens, level of immunogenetic indexes and morphologic changes of the thymus gland at myasthenia
DOI:
https://doi.org/10.7124/bc.0005D1Abstract
The key risk factors inducing the changes of thymus gland at myasthenia are different and their role is not studied completely. A possible correlation of isoantigen phenotypes HLA-DR with the character of ultrastructural pathology of thymus gland and the changes of immunoreactivity at myasthenia has been studied in this work. 70 % correlation with HLA-DR5 at the hyperplasia of thymus gland has been revealed. In patients with tumoral lesion of mediastinum the reliable increasing of IgE and IL-4 levels has been observed in 87.S % cases. A high level of correlation with isoantigen HLA-DR7 (66 %) has been revealed at thymomas.References
Balasa B, Deng C, Lee J, Bradley LM, Dalton DK, Christadoss P, Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med. 1997;186(3):385-91.
Kuzin MI, Geht BM. Myasthenia. M.: Meidtsina, 1996; 221 p.
Kharchenko VP, Sarkisov DS, Vetshev PS, Zarat'yants VA. Diseases of thymus. M.: Triada-X, 1998.
Rao VP, Balasa B, Carayanniotis G. Mapping of thyroglobulin epitopes: presentation of a 9mer pathogenic peptide by different mouse MHC class II isotypes. Immunogenetics. 1994;40(5):352-9.
Kaul R, Shenoy M, Goluszko E, Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J Immunol. 1994;152(6):3152-7.
Bonini S, Rasi G, Matficardl P. Infection and allergy. Int J Imraunorehabilit. 2001; 3(2): 35-42.
Lisak RP, Barchi RL. Myasthenia. Transl from English. M.: Meditsina, 1984. 270 p.
Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974;186(4158):55-7.
Sela M. Specific vaccines against autoimmune diseases. C R Acad Sci III. 1999;322(11):933-8.
Pinching AJ. Diseases of the neuromuscular junction: pathophysiological mechanisms of myasthenia gravis and Eaton-Lambert syndrome. Neurotransmitter systems. En NH Legga. M.: Meditsina, 1982: 26-38.
Yarilin AA. Apoptosis and its place in the immune processes. Immunologiiya. 1996; (6): 10-22.
Shevniuk MM, Krivitski? DI, Fedotov AF, Sil'chenko VP, Bobrik II. [Clinico-morphologic analysis of thymus tumors in patients with myasthenia]. Vrach Delo. 1988;(8):75-7.
Yarlin AA, Grinevitch YuA. Thymic structure and T-lymphocytes differentiation. K.: Naukova Dumka, 1991; 211 p.
Za?rat'iants OV, Vetshev PS, Popova IV, Ippolitov IKh, Voronov LI. [Cortical-cell thymomas with predominance of so-called nurse-cells in patients with myasthenia]. Arkh Patol. 1991;53(1):15-20.
Askarov SHA, Pinskaya LB, Turgunov AB. Genetic aspects of myasthenia. Med Zh Uzbekistana. 1989;5):62-4.
Kirchner T, Schalke B, Melms A, von K?gelgen T, M?ller-Hermelink HK. Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;52(3):237-57.
Konstantinova NA. Guidelines USSR Ministry of Health. M., 1986; 14 p.
Lmanskaya OYu, Limanskiy AN. Polymerase chain reaction with modified primers. Ul'trazvukovaya diagnostika. 1995; (6-7):71-7.
